Search research articles
Contact Us
Filters
Showing results (131-140 of 217) with videos related to
Page
of 22
Sort By:
Clinical Kidney Journal
|
February 13, 2019
Renal toxicities associated with pembrolizumab
Hassan Izzedine, Alexis Mathian, Stephane Champiat, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 3, 2025
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors
Ramez N Eskander, Jung-Yun Lee, Mansoor Raza Mirza, et al.
Journal for Immunotherapy of Cancer
|
July 2, 2024
Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer
Juan Francisco Grau Bejar, Elisa Yaniz Galende, Qinghe Zeng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2024
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low
Dione van Dijk, Lisa Vermij, Alicia León-Castillo, et al.
Future Oncology (London, England)
|
August 19, 2024
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer
Rayan Kabirian, Olivier Tredan, Frederik Marmé, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 22, 2023
Direct prediction of Homologous Recombination Deficiency from routine histology in ten different tumor types with attention-based Multiple Instance Learning: a development and validation study
Chiara Maria Lavinia Loeffler, Omar S M El Nahhas, Hannah Sophie Muti, et al.
Cells
|
June 25, 2020
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond <i>SMARCA4</i> Mutations: A Comprehensive Genomic Analysis
Aurélie Auguste, Félix Blanc-Durand, Marc Deloger, et al.
The Lancet. Oncology
|
October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Susana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.
Journal for Immunotherapy of Cancer
|
July 27, 2022
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
Laetitia Nebot-Bral, Antoine Hollebecque, Andrey A Yurchenko, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
June 30, 2018
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
Aurélie Auguste, Catherine Genestie, Marco De Bruyn, et al.
Page
of 22
Search research articles
Search
Showing results (131-140 of 217) with videos related to
Sort By:
Page
of 22
Clinical Kidney Journal
|
February 13, 2019
Renal toxicities associated with pembrolizumab
Hassan Izzedine, Alexis Mathian, Stephane Champiat, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 3, 2025
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors
Ramez N Eskander, Jung-Yun Lee, Mansoor Raza Mirza, et al.
Journal for Immunotherapy of Cancer
|
July 2, 2024
Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer
Juan Francisco Grau Bejar, Elisa Yaniz Galende, Qinghe Zeng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2024
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low
Dione van Dijk, Lisa Vermij, Alicia León-Castillo, et al.
Future Oncology (London, England)
|
August 19, 2024
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer
Rayan Kabirian, Olivier Tredan, Frederik Marmé, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 22, 2023
Direct prediction of Homologous Recombination Deficiency from routine histology in ten different tumor types with attention-based Multiple Instance Learning: a development and validation study
Chiara Maria Lavinia Loeffler, Omar S M El Nahhas, Hannah Sophie Muti, et al.
Cells
|
June 25, 2020
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond <i>SMARCA4</i> Mutations: A Comprehensive Genomic Analysis
Aurélie Auguste, Félix Blanc-Durand, Marc Deloger, et al.
The Lancet. Oncology
|
October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Susana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.
Journal for Immunotherapy of Cancer
|
July 27, 2022
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
Laetitia Nebot-Bral, Antoine Hollebecque, Andrey A Yurchenko, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
June 30, 2018
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
Aurélie Auguste, Catherine Genestie, Marco De Bruyn, et al.
Page
of 22